Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 2, 2012, Pages 817-825

  Ch'Ang, Hui Ju ^a,b   Hsu, Chiun ^c   Chen, Chien Hung ^c   Chang, Ya Hui ^a   Chang, Jeffrey S ^a   Chen, Li Tzong ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Angiogenic factors; Hepatocellular carcinoma; Inflammatory cytokines; Radiotherapy; Thalidomide

Indexed keywords

AFTER-TREATMENT; ANGIOGENIC FACTOR; ANTI-TUMOR ACTIVITIES; BASIC FIBROBLAST GROWTH FACTOR; BLOOD SAMPLES; CLINICAL OUTCOME; CLINICAL PARAMETERS; COMBINED THERAPY; COMBINED TREATMENT; CYTOKINES; DISEASE PROGRESSION; HEPATOCELLULAR CARCINOMA; INFLAMMATORY CYTOKINES; INTERLEUKIN-6; LEVEL-1; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PHASE II; PROGNOSTIC FACTORS; PROGRESSION FREE SURVIVAL; RESPONSE RATE; SKIN RASHES; THALIDOMIDE; TOTAL DOSE; TUMOR NECROSIS FACTORS;

BODY FLUIDS; CELL CULTURE; MULTIVARIANT ANALYSIS; RADIOTHERAPY; STEM CELLS;

TOXICITY;

FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; STEM CELL FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ERUPTION; EDEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; INFECTION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG EMBOLISM; MALAISE; MALE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIATION DOSE; RASH; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOKINE CXCL12; CHEMORADIOTHERAPY; CONSTIPATION; DISEASE-FREE SURVIVAL; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855842211     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.10.067     Document Type: Article

References (46)

1. G.C. Cook Hepatocellular carcinoma: One of the world's most common malignancies Q J Med 57 1985 705 708
2. T. Tsuzuki, A. Sugioka, and M. Ueda Hepatic resection for hepatocellular carcinoma Surgery 107 1990 511 520
3. M. Ohto, M. Yoshikawa, and H. Saisho Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients World J Surg 19 1995 42 46
4. K. Ikeda, H. Kumada, and S. Saitoh Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: An analysis by the Cox proportional hazard model Cancer 68 1991 2150 2154
5. J.M. Robertson, T.S. Lawrence, and L.M. Dworzanin Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy J Clin Oncol 11 1993 1286 1293
6. H.C. Park, J. Seong, and K.H. Han Dose-response relationship in local radiotherapy for hepatocellular carcinoma Int J Radiat Oncol Biol Phys 54 2002 150 155
7. S.H. Cheng, Y.M. Lin, and V.P. Chuang A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma J Gastroenterol Hepatol 14 1999 1025 1033
8. J. Seong, H.C. Park, and K.H. Han Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients Int J Radiat Oncol Biol Phys 55 2003 329 336
9. K. Aoki, N. Okazaki, and S. Okada Radiotherapy for hepatocellular carcinoma: Clinicopathological study of seven autopsy cases Hepatogastroenterology 41 1994 427 431
10. J. Chia-Hsien Cheng, V.P. Chuang, and S.H. Cheng Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization Int J Cancer 96 2001 243 252
11. Y.L. Chung, J.J. Jian, and S.H. Cheng Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma Clin Cancer Res 12 2006 2706 2715
12. O.N. El-Assal, A. Yamanoi, and Y. Soda Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver Hepatology 27 1998 1554 1562
13. R.T. Poon, I.O. Ng, and C. Lau Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study Ann Surg 233 2001 227 235
14. J.C. Cheng, C.H. Chou, and M.L. Kuo Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway Oncogene 25 2006 7009 7018
15. R.J. D'Amato, M.S. Loughnan, and E. Flynn Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
16. B.M. Kenyon, F. Browne, and R.J. D'Amato Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Exp Eye Res 64 1997 971 978
17. S. Singhal, J. Mehta, and R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
18. R.F. Little, K.M. Wyvill, and J.M. Pluda Activity of thalidomide in AIDS-related Kaposi's sarcoma J Clin Oncol 18 2000 2593 2602
19. C. Hsu, C.N. Chen, and L.T. Chen Low-dose thalidomide treatment for advanced hepatocellular carcinoma Oncology 65 2003 242 249
20. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
21. D.H. Gorski, M.A. Beckett, and N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
22. H.J. Mauceri, N.N. Hanna, and M.A. Beckett Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287 291
23. S. Kinuya, A. Kawashima, and K. Yokoyama Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts J Nucl Med 43 2002 1084 1089
24. J.I. Lee, S. Itasaka, and J.T. Kim Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model Oncol Rep 15 2006 1163 1168
25. J.P. Knisely, B. Berkey, and A. Chakravarti A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118) Int J Radiat Oncol Biol Phys 71 2008 79 86
26. S.M. Chang, K.R. Lamborn, and M. Malec Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 60 2004 353 357
27. Y.F. Liaw, D.I. Tai, and T.J. Chen Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma Liver 6 1986 133 137
28. K. Okuda Early recognition of hepatocellular carcinoma Hepatology 6 1986 729 738
29. American Joint Committee on Cancer Manual for Staging of Cancer 6th ed. 2009 Lippincott Philadelphia
30. R.N. Pugh, I.M. Murray-Lyon, and J.L. Dawson Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
31. H.S. Shiah, Y. Chao, and L.T. Chen Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma Cancer Chemother Pharmacol 58 2006 654 664
32. Cancer Therapy Evaluation Program. Common toxicity criteria, version 3.0. Accessed August 9, 2006. Available from: National Cancer Institute: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-30.
33. A.B. Miller, B. Hoogstraten, and M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
34. H.E. Chiou, T.E. Wang, and Y.Y. Wang Efficacy and safety of thalidomide in patients with hepatocellular carcinoma World J Gastroenterol 12 2006 6955 6960
35. P. Kumar, A.I. Miller, and P.J. Polverini p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway J Biol Chem 279 2004 43352 43360
36. R.J. Griffin, B.W. Williams, and R. Wild Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response Cancer Res 62 2002 1702 1706
37. C.G. Lee, M. Heijn, and E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
38. M.S. O'Reilly, L. Holmgren, and C. Chen Angiostatin induces and sustains dormancy of human primary tumors in mice Nat Med 2 1996 689 692
39. J. Folkman, and K. Camphausen Cancer: What does radiotherapy do to endothelial cells? Science 293 2001 227 228
40. R. Ansiaux, C. Baudelet, and B.F. Jordan Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment Clin Cancer Res 11 2005 743 750
41. N. Crokart, K. Radermacher, and B.F. Jordan Tumor radiosensitization by antiinflammatory drugs: Evidence for a new mechanism involving the oxygen effect Cancer Res 65 2005 7911 7916
42. A.X. Zhu, D.V. Sahani, and D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study J Clin Oncol 27 2009 3027 3035
43. A. Sutton, V. Friand, and S. Brule-Donneger Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion Mol Cancer Res 5 2007 21 33
44. C. Porta, M. De Amici, and S. Quaglini Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma Ann Oncol 19 2008 353 358
45. A.B. Siegel, E.I. Cohen, and A. Ocean Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
46. B.P. Schneider, M. Wang, and M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678